Nancy Agmon-Levin

1 month ago | onlinelibrary.wiley.com | Raffi Tachdjian |Aleena Banerji |Paula J. Busse |Nancy Agmon-Levin

There is currently a shortage of data on long-term prophylaxis outcomes in adolescents with hereditary angioedema (HAE). In this study, we employed pooled data from 2 real-world observational studies to assess the effectiveness and safety of lanadelumab in preventing HAE attacks in patients aged 12–17 years with HAE-C1INH.